IMNN Imunon
Imunon earnings company data as of 4:48 AM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by IMNN's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $38K sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Susan Eylward General Counsel and Corp SecSale$3,950 2,525 shares at $1.56 47% of stakeTraded Aug 31 Filed Sep 1
-
Susan Eylward General Counsel and Corp SecSale$3,993 2,449 shares at $1.63 46% of stakeTraded Aug 17 Filed Aug 17
-
Susan Eylward General Counsel and Corp SecSale$3,977 2,541 shares at $1.57 47% of stakeTraded Aug 3 Filed Aug 4
-
Susan Eylward General Counsel and Corp SecSale$3,830 2,150 shares at $1.78 43% of stakeTraded Jul 20 Filed Jul 21
-
Susan Eylward General Counsel and Corp SecSale$1,730 920 shares at $1.88 24% of stakeTraded Jul 6 Filed Jul 7
-
Susan Eylward General Counsel and Corp SecSale$21K 11,800 shares at $1.75 80% of stakeTraded Jun 29 Filed Jun 29
Also filed in the last 12 months, not counted as buying or selling: 47 stock grants.
SEC filings
Recent issuer filings from EDGAR, 7 shown.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.